icon
icon
icon
icon
🏷️$300 Off
🏷️$300 Off

News /

Articles /

Gilead and Merck's Promising Partnership: A New Chapter in HIV Treatment

Word on the StreetSaturday, Oct 19, 2024 6:00 pm ET
1min read

Gilead Sciences has announced promising results from its study on an oral treatment for HIV, involving a combination of islatravir and lenacapavir. The study, conducted in collaboration with Merck & Co, is a phase 2 clinical trial aimed at evaluating the safety and antiviral efficacy of this once-weekly oral regimen in adults with HIV-1 who have achieved virologic suppression through antiretroviral therapy.

The trial is the first in the partnership between Merck and Gilead, established in March 2021, focusing on developing potential long-acting HIV treatments. The companies believe that long-acting therapies could mark a significant breakthrough in the development of HIV medications, building on the traditional foundations of HIV care.

Islatravir, developed by Merck, is an investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), designed for combination therapy in treating individuals with HIV-1 infection. Meanwhile, lenacapavir, developed by Gilead, is a long-acting HIV-1 capsid inhibitor, currently under review in both the U.S. and the EU for use alongside other antiretroviral drugs in patients with multidrug-resistant HIV-1.

Both islatravir and lenacapavir exhibit extended half-lives and have demonstrated activity at low doses in independent clinical studies, supporting their development as long-acting combination therapies, including oral and injectable forms. While daily oral regimens are available to HIV patients, the prospect of less frequent dosing could address preferences related to stigma, adherence, and privacy.

Jared Baeten, MD, VP of HIV Clinical Development at Gilead, stated that partnerships are crucial in making significant advances towards ending the HIV epidemic. This research collaboration is a testament to the ongoing advancements in HIV science, aiming to provide long-acting options that cater to the diverse needs and preferences of individuals living with HIV.

Joan Butterton, MD, VP of Global Clinical Development of Infectious Diseases at Merck Research Laboratories, emphasized that the initiation of this study is essential for further understanding the potential of islatravir and lenacapavir in joint HIV-1 treatment. It signifies Merck and Gilead's commitment to addressing unmet needs among people with HIV and contributing to global efforts to end the epidemic.

Comments

Add a public comment...
Post
No Comment Yet
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App